To survive in a very competitive environment, marine macroalgae had to evolve defense strategies, resulting in an enormous diversity of compounds from different metabolic pathways. These secondary metabolites have been explored by the pharmaceutical industries in order to generate new drugs to treat several diseases. Recent publications in drug research from natural sources have indicated algae as an interesting choice to provide novel drugs to fulfill this gap. This review highlights algal metabolites that showed bioactivities suggesting their potential against neglected diseases. Drug discovery for neglected diseases has been overlooked by the Big Pharmas, mainly because they affect poor people, most of them living in developing countries. Moreover, this review shows the commercial application of the most explored chemicals from algae such as terpenes, phenols, quinones, macrolides, alkaloids, lipids, chromones, and other related metabolites and an overview regarding the status of green extraction technologies for seaweeds and their concepts.
Introduction
This review describes natural products (NPs) obtained from macroalgae through activity-driven approach or semisynthetic synthesis and available in the public literature or in the database of patents, PATENTSCOPE (World Intellectual Property Organization), encompassing the period from 1998 to 2018. The search criterion adopted was the evaluation of bioactivities of chemically defined compounds against human pathogenic bacteria, fungi, protozoa, and helminthes. Bioactive compounds against model organisms were included, even those not directly related to neglected diseases (NDs) due to the low number of articles approaching their etiologic agents. Finally, articles reporting evaluation of extracts/fractions or compounds without bioactivity or positive controls were excluded.
Human actions and their consequences on neglected diseases
The world's population has increased exponentially and reached nearly 7.6 billion people in 2017 and projected to reach 8.6 billion people by 2030 (United Nations, 2017) . Furthermore, growth in human population is causing unplanned and poorly managed urbanization, mainly in developing countries, putting millions of people to live in areas with poor infrastructure. It is estimated that the percentage of people living in urban areas will increase from 54% in 2015 to 66% by 2050 (WHO 2014) , contributing to the worsening infrastructure problems, climate changes, and emergence of vector-borne diseases (i.e., leishmaniasis/malaria), soil-transmitted helminthic infections (i.e., ascaridiasis/strongyloidiasis), and food-and water-borne illness (i.e., amoebiasis/giardiasis), among other NDs caused by bacteria and fungi (yaws/mycetoma) (Foley et al. 2005; Pinto et al. 2005 Pinto et al. , 2011 Oryan and Akbari, 2016) (Fig. 1) . According to the World Health Organization, NDs are endemic in 149 countries and affect more than one billion people worldwide (http://www.who.int/neglected_ diseases/diseases/en/) by (WHO 2018) . Chemotherapy is the main approach used to control and overcome the deleterious effect of these NDs; however, its lack of efficacy and several side effects contribute to the elevated index of mortality and morbidity among people in the developing countries.
In 2012, global health partners from public, private, and nonprofit sectors signed BThe London Declaration on Neglected Tropical Diseases^, a document containing their commitment to control, eliminate, or eradicate NDs by 2020 and improve the quality of life of billions of people (http://unitingtocombatntds.org/london-declarationneglected-tropical-diseases/). However, despite all the efforts, new therapies for NDs are still far from the ideal, as depicted in Fig. 2 , which shows the limited number of new chemical entities approved by regulatory agencies for NDs in a period of 30 years encompassing 1984 (Newman and Cragg, 2016 .
Another point to be considered that impacts even more the drug discovery process for NDs refers to the shift of strategy adopted by the pharmaceutical companies in the 80s that emphasized high throughput screening (HTS) of synthetic libraries, which present limited structure diversity when compared to the chemical space presented by the NPs (Baker, 1984; Li and Vederas, 2009 ). Historically, NPs from different sources have made important contributions to the therapeutical arsenal to treat diverse diseases, including antibiotics (e.g., penicillin, tetracycline, erythromycin) and antiparasitics (e.g., avermectin, quinine, artemisinin), as well as contributed to the development of many analogs synthesized inspired on NPs such as the antimalarial mefloquine and the candidate artefenomel, currently in phase II clinical trial for malaria treatment (Mccarthy et al. 2016; Macintyre et al. 2017 ). According to Newman and Cragg (2016) , 26% of analogs derived from NPs have been approved by the American regulatory agency FDA from 1984 to 2014; together, NPs or those molecules derived by semi-synthesis or inspired on NPs correspond to 51% of the total approved drugs (Newman and Cragg, 2016) . Until the decade of 1990, these numbers were around 80%, dropping dramatically to nearly 50% from the moment that the pharmaceutical companies have shifted their strategy from NPs to medicinal chemistry approach (Li and Vederas, 2009 ).
Macroalgae as a renewable source of high-value compounds
Macroalgae NPs have been widely explored and afforded many chemicals and products with high aggregated value including fibers, minerals, antioxidants, vitamins, pigments, steroids, lectins, halogenated compounds, polyketides, polysaccharides, mycosporine-like amino acids, proteins, polyunsaturated fatty acids, and other lipids (Cardozo et al. 2007 ). Furthermore, isolated compounds obtained through activity- Fig. 1 Major forces that drive the emergence, re-emergence, and spread of insect-, water-, and food-borne diseases and their impacts guided isolation process have shown sophisticated chemical structures and great potential in the pharmaceutical areas including drugs for NDs (Tanaka et al. 1975; Cardozo et al. 2007; Gressler et al. 2011a Gressler et al. , 2011b Torres et al. 2014) . Due to the different uses and wide availability of these photosynthetic organisms, the interest has turned from wild harvest to farming and controlled cultivation.
In order to obtain algae in large scale cultivation in open ponds, photobioreactors, or tanks applying integrated multi-trophic aquaculture (IMTA) has been adopted (Rorrer et al. 1995; Huang and Rorrer, 2002; Fernandes et al. 2017) . Although advantages and disadvantages in each of these cultivation methods exist, they definitely have changed the concept from the wild harvesting to the sustainable production of algae. The great advantage of any cultivation technique is to avoid overexploitation of natural algae resources. Additionally, cultivation can also promote the selection of germplasm of the desired algae in the laboratory and therefore their use as seed stock (Tomazela et al. 2000) . Thus, algae producing secondary metabolites important for human being can be generated as seeds in laboratory and then transferred to cultivation areas (Fernandes et al. 2017) .
Additionally to the presence of the aforementioned highvalue products, macroalgae are little affected by seasonality and have both high productivity (biomass production) and capacity to capture CO 2 (Martins et al. 2016 ). These features are pivotal when one looks for a feedstock inserted in a sustainable supply chain. Nowadays, considering the concept of Bbioeconomy^and its strategies, not only the biomass production has to be environmentally friendly but also the entire bioprocess must be sustainable, maximizing the valorization of raw material. The development of new technologies (breakthrough or disruptive innovation) or improvement of existing ones (incremental innovation) and the design of extractions processes that efficiently recover not just the target compound but also co-products and by-products are mandatory (PrietoSandoval et al. 2018) .
Green extraction technologies applied to macroalgae processing
Green extraction is based on principles that contemplate (i) the use of renewable plant resources (e.g., seaweeds), (ii) the use of alternative solvents replacing petrochemicals ones, (iii) the reduction of both energy consumption, (iv) business unit operations, and (v) the transformation of waste residue into co-products and by-products via processes that (vi) do not degrade nor contaminate the raw material (Gorka and Wieczorek, 2017; Ospina et al. 2017) . These features are in complete agreement with the concept of circular economy, which demands eco-friendly innovations and sustainable feedstock as macroalgae to close the loop of the products lifecycle (Prieto-Sandoval et al. 2018) (Fig. 3) .
In this context, supercritical fluid extraction (SFE), microwave-assisted extraction (MAE), ultrasound-assisted extraction (UAE), and pressurized liquid extraction (PLE) are examples of green technologies that have been used in seaweed NPs research (Table 1) .
Supercritical fluids are among the best green alternatives to substitute organic solvents for seaweed processing (Table 1) . To be considered in its critical state, a solvent has to surpass its critical temperature (T c ) and pressure (P c ) (Chemat et al. 2017) . Different combinations of these physical properties can be used to modulate the selectivity of the extraction. Although any solvent, including the petrochemical ones, can be used as a supercritical fluid, CO 2 is the most used because of its Fig. 2 Disease burden and number of developed New Chemical Entities (NCEs) for major diseases from 1984 to 2014, adapted from Newman and Cragg (2016) safeness (does not interact with the matrix nor remain on the extraction residue), high availability, and reasonable costs (Pereira and Meireles, 2010) . CO 2 in the supercritical state (T c = 304.1 K and P c = 7.37 MPa) might present a non-polar feature similar to hexane, which means that it can be a natural substitute. In addition to the temperature and pressure parameters, green co-solvents such as ethanol or water have been used to enhance the fluid's polarity and by this manner extend the range of added value compounds that can be extracted from seaweeds (Anaelle et al. 2013; Becerra et al. 2015; Sivagnanam et al. 2015; Ospina et al. 2017) .
Recently, it has been demonstrated that the use of SFE in a biorefinery concept at a first step of processing has a positive effect on downstream technologies during annatto seed valorization (Albarelli et al. 2016) . It is tempting to consider the same scenario for the seaweeds. After the extraction of non-and semi-polar added value bioactive compounds such as essential oils, carotenoids, antioxidants, antiparasitic, antibacterial, and others (Table 1) , the remaining residue is a by-product that contains valuable polar compounds, e.g., phycobiliproteins and carrageenan (Boulho et al. 2017; Mittal et al. 2017 ) and others (antioxidants, biopolymers, antibacterial, antiparasitic, and antiviral compounds) ( Table 1 ) that could be complementarily extracted by MAE, UAE, and PLE as downstream technologies.
Despite the fact that microalgae and seaweed are considered renewable and valuable feedstock, they have been poorly explored in the biorefinery concept. To overcome it, some efforts have been done regarding microalgae such as Scenedesmus obliquus (Gilbert-Lopez et al. 2017) and Nannochloropsis sp. (Ferreira et al. 2013) as well as the seaweeds Ulva lactuca (Bikker et al. 2016; Postma et al. 2018) and Saccharina latissima (Sterner et al. 2016 ).
Antibacterial, antifungal, and antiparasitic NPs isolated from seaweed: a contribution of marine resources against NDs
This topic discusses antibacterial, antifungal, and antiparasitic bioactive compounds from macroalgae encompassing the period of 1998 to the present and is organized by chemical class and then by their bioactivities. As depicted below, the number of bioactive compounds is higher for antibacterial activity rather than for the other etiologic agents herein approached. It is worth to mention that although most of the articles about antibacterial and antifungal compounds present a bias to Escherichia coli/ Staphylococcus aureus and Candida albicans, the value of this information is inestimable, considering the potential of development of new antibacterial, antifungal, and even antiparasitic agents with wide spectra of action based on evolutionary similarities among these microorganisms and their pathogenic counterparts known to cause NDs (Mobegi et al. 2017) . Furthermore, other important etiologic agents of NDs are also missing in this review due to the lack of articles on organisms such as Treponema pallidum, Paracoccidioides brasiliensis, Trypanosoma brucei, or Schistosoma mansoni. The inclusion of microorganisms other than NDs is important not only to contribute to macroalgal researchers focused on ND, providing what is known regarding bioactive compounds on model microorganisms, but also to point out that it is possible to correlate such information as a short cut in drug discovery to ND, since many metabolic pathways are known to be shared by both parasites and bacteria. Indeed, some antibiotics known to be active against bacteria, for instance, are active against Apicomplexa parasites. This group of parasites, including pathogens like Plasmodium spp. and Toxoplasma gondii, has a relict non-photosynthetic plastid, the apicoplast that contains a Santoyo et al. (2011) few processes that are clearly bacterial in nature and, therefore, potential targets for new (or existing) antibiotics including a set of prokaryotic-/plant-like metabolic pathways for fatty acid, isoprenoid precursors, heme, and Fe/S cluster synthesis among other roles in DNA, RNA, and protein metabolism (Chakraborty 2016) . The bioactive compounds presented in the following section were classified as Bterpenes^, Bphenols, quinones, chromones, and other rel a t e d m e t a b o l i t e s^, Bm a c r o l i d e s^, Ba l k a l o i d s^, Bpolysaccharides^, and Blipids^( Table 2) .
Terpenes
Halogenated sesquiterpenes are among the most interesting antimicrobial compounds reported in the reviewed literature. König et al. (2000) showed that, among 39 marine NPs, 17 were isolated from the genus Laurencia (Rhodomelaceae). The compounds elatol (1), deschloroelatol (2), allolaurinterol (3), and debromolaurinterol (4) presented anti-Mycobacterium tuberculosis and anti-Mycobacterium avium activities, with minimum inhibitory concentration (MIC) ranging from 16 to 64 μg mL −1 , with 3 the most active compound (MIC = 16 μg mL −1 ). Ventura et al. (2015) showed that among the halogenated sesquiterpenes isolated from Laurencia drendoidea collected in the Southern Eastern of Brazil, obtusol (5) was bioactive against Mycobacterium bovis (IC 50 = 31 μg mL − 1 ) and M. tuberculosis (IC 50 = 97 μg mL −1 ). Interestingly, 5 was less active than the crude extract, which might be due to synergistic interactions with other compounds contained in the crude extract. Compound 5 (IC 50 = 4 μg mL −1 ) was also as active as the reference drug potassium antimony(III) tart r a t e ( I C 5 0 = 3 μ g mL − 1 ) against L e i s h m a n i a amazonensis intracellular amastigotes (Da Silva Machado et al. 2011) ; additionally, dos re ported t hat 1 wa s a ctive against L. amazonensis amastigotes (IC 50 = 0.5 μM), while VeigaSantos et al. (2010) mentioned its anti-Trypanosoma cruzi amastigote activity (IC 50 = 1 μM). The potency of 1 was similar to the reference drug amphotericin B for L. amazonensis and 24 times more active than benznidazole for T. cruzi. In trypomastigotes of T. cruzi, 1 seems to cause depolarization of the mitochondrial membrane potential and increase the levels of reactive oxygen species (Desoti et al. 2012) . Although the possible molecular target of 1 is the mitochondrion and considering that this organelle is present in both parasites and their hosts, the authors claim that this molecule does not show any cytotoxic effect, which could be explained based on the differences between parasite and mammalian mitochondria (Inoki et al. 1958; Stoppani et al. 1980; Barros-Alvarez et al. 2014; Docampo and Huang, 2015) . Other works have reported the cytotoxicity of 1 (Lang et al. 2012; Campos et al. 2012 ).
The investigation of the antimicrobial activity of the major metabolites of Laurencia majuscula, 1, and iso-obtusol (6) showed similar activity towards the clinical isolates Klebsiella pneumonia, Salmonella sp., and Staphylococcus epidermidis when compared to commercial antibiotics (Vairappan, 2003) . In a subsequent work, this author reported the antibacterial activity of other Laurencia spp. halogenated sesquiterpenes, among them laurinterol (7), allolaurinterol (3), isolaurinterol (8), and cupalaurenol (9). These compounds showed wide spectra of activity against Gram-positive bacteria, including vancomycin-susceptible strains such as methicillin-resistant Staphylococcus aureus, penicillinresistant Streptococcus pneumoniae, and Enterococcus strains, regardless their phenotype of resistance to vancomycin (Vairappan et al. 2004 ). Chen et al. (2016) isolated eight new halogenated chamigrane sesquiterpenes, a new bromocuparane, and nine known related metabolites from Laurencia tristicha collected in Taiwan and tested against Enterobacter aerogenes, Yersinia enterocolitica, and Serratia marcescens. The chamigrane 10 had half of the activity of ampicillin towards Y. enterocolitica, while the known secondary metabolites 11 and 12 were able to inhibit the growth of the bacteria S. marcescens similarly to ampicillin (Chen et al. 2016 ). Davyt et al. (2001) isolated eight sesquiterpenes β-chamigrane-type from the dichloromethane extract of Laurencia scoparia and demonstrated their activity against the parasitant stage of the helminth model Nippostrongylus brasiliensis. The compounds 13-15 are novel NPs, while other 16-21 are well-known chamigranes. All compounds showed moderate in vitro anthelmintic activity (IC 50 < 100 μM) and none of them was as active as the reference drug albendazole (IC 50 = 0.34 μM). Based on the structure of the compounds, the authors also considered that between the ND not determined a Selective index isomeric pairs, 14-15 and 16-17, the Z-isomers 14 and 16 were more active than the E-isomers 15 and 17 (Davyt et al. 2001) . The same authors (2006) reported the isolation of three new halogenated β-bisabolene sesquiterpenoids from L. scoparia. Compound 22 exhibited weak in vitro anthelmintic activity against parasitant stage (L4) N. brasiliensis (IC 50 = 0.11 mM) when compared to the positive control reported in the previous work (Davyt et al. 2001 (Davyt et al. , 2006 . Bawakid et al. (2017) , working with Laurencia obtusa from the Saudi Red Sea, isolated four new sesquiterpenes and further evaluated against multidrug-resistant bacteria strains including S. aureus, Enterococcus faecalis, and Pseudomonas aeruginosa. They showed that compound 23 (MIC = 0.09 μM) was as active as amoxicillin when tested towards S. aureus, while the eudesmane sesquiterpene 24 (MIC = 8.3 μM) showed nearly half of the anticandidal activity of amphotericin B (MIC = 4.7 μM). , overwhelming the positive control norfloxacin. In face of the less active bromoditerpenes, the authors argue that the presence of α,β-unsaturated ketone at C-12 might be contributing to the observed activity, with this compound being capable of undergoing Michael-type additions to this moiety via attack at C-14 by biological nucleophiles (Smyrniotopoulos et al. 2008) . Following the investigation, four new tetracyclic bromoditerpenes (26-29) modified at C-12 have also shown antibacterial activity against the same panel of S. aureus strains; however, this activity was only four to 16 times higher than norfloxacin, contrary to previous work that showed 25 was 64 to 512 times more active than the same standard drug (Smyrniotopoulos et al. 2010) . These findings are corroborated by Rodrigues et al. (2015) who showed other bromoditerpenes without ketone at C-12 are not active against bacteria species including E. coli and P. aeruginosa, while the known compound 30 was only as effective as ampicillin when tested against S. aureus.
Awad (2004) isolated novel brominated diterpenes parguerene and isoparguerene from the red alga Jania rubens, collected from the Red Sea coasts, Egypt. The compounds were identified as isoparguerol (31), isoparguerol-16-acetate (32), isoparguerol-7, 16-diacetate (33), parguerol-16-acetate (34), parguerol-7, 16-diacetate (35), deoxyparguerol (36), and deoxyparguerol-7-acetate (37) and tested for anthelmintic activities against the earthworms Allolobophora caliginosa. Compounds 31-35 were more effective than 36 and 37 and gave high anthelmintic activity when compared with the same concentration (10%) of the reference drug mebendazole. Ioannou et al. (2011) isolated 17 dolabellanes, including eight novel compounds, from the brown alga Dilophus spiralis (synonym: Dictyota spiralis Montagne) from Elafonissos Island, Greece (Guiry and Guiry, 2018) . The compounds were tested against a panel of six strains of S. aureus presenting different phenotypes regarding drug susceptibility. Compound 38 bears a ketone group at C-14 and was eight times more active than norfloxacin against the methicillinresistant strain, EMRSA-16, and its alcohol derivative 39 was the most active compound against all six strains; however, when compared to the reference drug, 39 was more effective than norfloxacin (64 times) only for the EMRSA-16 strain. The most active compounds against EMRSA-16 bear a hydroxyl group at C-12 (40), C-14 (39 and 41), or C-18 (42 and 43), suggesting that these structural features seem to be important for the activity of these dolabellanes against the strain EMRSA-16; nevertheless, these structure-activity relationships (SAR) are not essential, since compound 44 bears an epoxide function instead of a double bond at C-7, unlikely the aforementioned structural feature. Compound 40 was moderately active against all tested strains and differs from 39 by the position of the hydroxyl group. Following the exploitation of the same alga D. spiralis, Ioannou et al. (2012) isolated 13 other novel minor dolabellanes, which were tested against the same panel of S. aureus strains from their previous work (Ioannou et al. 2011) . Among all tested compounds, only 45 and 46 were 64 times more active than norfloxacin against EMRS-16 as well as to two other multidrug-resistant strains and were as active as the standard drug. Regarding the SAR, the author suggests that the allylic hydroxyl group at C-7 might be contributing to the antibacterial activity; additionally, compounds presenting a ketone group at C-14 such as 47 were inactive. Soares et al. (2012) semi-synthesized dolabelladienetriol (48) after reduction of dolabellane diterpene 10,18-diacetoxy-8-hydroxy-2,6-dolabelladiene obtained from the brown algae Dictyota pfaffi as previously described (Barbosa et al. 2004) . Compound 48 was active against promastigotes and intracellular amastigote forms of L. amazonensis and was also effective in reducing amastigotes in HIV-1-infected human macrophages.
Dos Santos et al. (2011) isolated the diterpene 49 from the brown alga Canistrocarpus cervicornis, collected in the coast of Paraíso Beach, Pernambuco State, Brazil, which showed a dose-dependent activity against promastigotes, axenic amastigotes, and intracellular amastigotes of L. amazonensis. Despite the fact that 49 was two times less active than amphotericin B, the compound presented an outstanding selective index (SI = 93), i.e., 49 was 93 times more selective to the parasite rather than to the J774G macrophages and it is suggested that the antileishmanial effect is also related to the depolarization of the mitochondrial membrane and membrane lipid peroxidation. Gallé et al. (2013) demonstrated that eleganolone 50 obtained from the brown alga Bifurcaria bifurcata showed interesting anti-Plasmodium falciparum activity (IC 50 = 2.6 μg mL −1 ; SI = 22) and low cytotoxicity, being 22 times more selective to the parasite. Although 50 presented moderate activity against both Trypanosoma brucei rhodesiense (IC 50 = 13.7 μg mL − 1 ; SI = 4) and T. cruzi (IC 50 = 18 μg mL −1
, SI = 3), the diterpene was cytotoxic to the host cell, according to the obtained SI. Smyrniotopoulos et al. (2017) isolated bifurcatriol (51) from the Irish brown alga B. bifurcata. Compound 51, which has two stereogenic centers, was tested towards the protozoa P. falciparum (IC 50 = 0.65 μg mL −1 ; SI = 877), T. brucei rhodesiense (IC 50 = 12 μg mL −1 ; SI = 5),
T. cruzi (IC 50 = 48 μg mL −1 , SI = 1), and Leishmania donovani (IC 50 = 19 μg mL −1 ; SI = 3). Compound 51 did not present wide spectra of action, being more active only against the malaria parasite; additionally, although 51 was not as active as chloroquine (IC 50 = 50 μg mL −1 ), its selectivity was outstanding (SI = 877). Puglisi et al. (2004) isolated the triterpene sulfate cycloartanone capisterones A (52) and B (53) from the green alga Penicillus capitatus, collected in Sweetings Cay, Bahamas. In order to search for efflux pumps inhibitors, Li et al. (2006) tested these compounds towards a panel of different fungi, including Candida albicans, Candida glabrata, Candida krusei, Cryptococcus neoformans, and Aspergillus fumigatus as well as against two fluconazole-resistant strains of Saccharomyces cerevisiae overexpressors of the efflux pumps CDR1 and MDR1 of C. albicans. Interesting, both 52 and 53 were able to reverse the drug resistance phenotype of the S. cerevisiae strains; however, they did not present any antifungal activity against the other fungi species tested, which suggests that these compounds might be acting as efflux pumps inhibitors. Becerra et al. (2015) obtained fucosterol (54) from the brown alga Lessonia vadosa from Patagonia, through green extraction methods. The triterpene presented antileishmanial activity towards Leishmania infantum (IC 50 = 10 μM; SI > 10) and L. amazonensis (IC 50 = 8 μM; SI > 12). Although its efficacy is low compared to amphotericin B (IC 50 < 0.2 μM), the SI values higher than ten turn it an interesting scaffold for the drug development process.
Phenols, quinones, chromones, and other related metabolites
The brown alga Sargassum sagamianum from Japan afforded the known sargaquinoic acid (55) and sargachromenol (56) and two new sargaquinoic acid derivatives, 15′-hydroxysargaquinolide (57), and the product of its oxidative cleavage (58). The antibacterial assays were performed against S. aureus and showed that these compounds present MIC values ranging from 2 to 32 μg mL , and among them, 58 was the most potent (MIC = 2 μg mL −1 ), considering the positive control vancomycin
) (Horie et al. 2008 ). Kamei et al. (2009) isolated from Sargassum macrocarpum from Japan, sargafuran (59), a compound presenting a similar side chain to sargaquinoic acid (55) and sargachromenol (56). The compound 59 presented bactericidal activity against Streptococcus pyogenes that causes acne, unlikely clindamycin, known to have only bacteriostatic activity. The bactericidal activity of 59 is highlighted because it might contribute to minimize the emergence of resistant strains.
From another red alga, Symphyocladia latiuscula, collected at Qindao, China, Xu et al. (2014) isolated bromophenols that presented antifungal activity towards C. albicans. The new metabolite 60 showed mild antifungal activity (MIC = 25 μg mL −1 ), while the known compound 61 was two times more active (MIC = 12.5 μg mL −1 ) than 60; however, both bromophenols were less active than the positive control fluconazole (MIC = 0.5 μg mL −1 ). Liu et al. (2013) showed that the isolated prenylated pxylene caulerprenylol B (62) from the green alga Caulerpa racemosa from China was as active as amphotericin B (MIC 80 = 4 μg mL −1 ) against C. neoformans (MIC 80 = 4 μg mL
) and only two times lower than the reference drug (MIC 80 = 2 μg mL ). Soares et al. (2016) studying the lipophilic extract from the brown Stypopodium zonale, collected in Brazil, described the isolation of meroditerpenoid atomaric acid (63) and its methyl ester derivative (64). Both compounds showed comparable anti-L. amazonensis amastigote activity (IC 50 = 20 μM) but 20 times lower than amphotericin B. Although the activity of the compounds is mild, they were at least eight times more selective to the parasite, which might be interesting in terms of further drug development process.
de Sousa et al. (2017) described bioactivity-driven fractionation of the hexane extract from the brown alga Cystoseira baccata collected in Portugal and reported the anti-L. infantum activity of the meroditerpenoid tetraprenyltoluquinol (65). This compound was nearly as active (IC 50 = 25 μM) as miltefosine (IC 50 = 20 μM) against intracellular L. infantum amastigotes and was five times more selective to the parasite than to the host cells. Afolayan et al. (2008) isolated the tetraprenylated toluquinols, sargaquinoic acid (55), sargahydroquinoic acid (66), and sargaquinol (67) and the carotenoid pigment fucoxanthin (68) from the brown alga Sargassum heterophyllum, collected in of South Africa. The compounds were tested towards the parasite P. falciparum, and although all of them presented antiplasmodial activity, the most active were 67 (IC 50 = 0.8 μg mL ), considering the activity of chloroquine (IC 50 = 9 ng mL −1 ), being 68 the most selective to the parasite (SI = 54). Table 3 Representative patents regarding green extraction methods used on seaweeds were also active against P. falciparum chloroquine-resistant parasites, indicating that bromophycolide A might not be substrate to efflux pumps, which are known to be involved in parasite resistance to chloroquine. In addition to the low toxicity of these compounds over mammalian cells, the author's data support the hypothesis that the structure of bromophycolides might be considered as inhibitors of heme crystallization, similarly to artemisin.
Alkaloids
From the red alga Laurencia similis, Li et al. (2016) isolated four new minor brominated indole related alkaloids and tested them against three Gram-positive and four Gram-negative bacterial strains. Brominated indole 74 presented MIC values ranging from 2 to 4 μg mL −1 and was at least 31 times more potent than penicillin (MIC = 250 μg mL ) for all Gram-negative bacteria tested; however, no remarkable effect was observed for any of the compounds considering the Gram-positive strains. ). Another red alga from China, Chondria crassicaulis, was investigated by Tong et al. (2017) and afforded two pairs of rare racemic lipids, derivatives of heptanediones. These compounds were tested against different clinical isolates, including four species of Candida. One of the racemic heptanedione derivatives, 77, had moderate activity against C. neoformans (MIC 80 = 32 μg mL ). A mixture of three sulfoquinovosyl-diacylglycerols 78-80 isolated from the chloroform fraction of the total extract of the brown alga Lobophora variegata showed good activity against Entamoeba histolytica (IC 50 = 3.9 μg mL −1 ), moderate activity against Trichomonas vaginalis (IC 50 = 8.0 μg mL −1 ), and good selectivity to the parasite (SI > 10); however, the mixture was not as effective as the reference drug metronidazole (CantilloCiau et al. 2010 ), were obtained for Vibrio cholerae (MIC = 31.3 μg mL −1 ) and P. aeruginosa (MIC = 62.5 μg mL −1 ).
The original fucoidans from Saccharina (Laminaria) japonica showed no antibacterial activity at the concentration of 10 mg mL
, but interestingly, the products of depolymerization (fractions with molecular weight ranging from < 6 up to > 80 kDa) showed some activity against S. aureus and E. coli with the best results associated to the fraction with lower molecular weight ). Based on their results and considering the literature reports for fucoidans from other algae, the authors suggest that both sulfate content and molecular weight are the main factors that contribute to the antibacterial activity of fucoidans. Chen et al. (2009) showed the antiplasmodial activity of the sulfated polysaccharide fucoidan obtained from the brown alga Undaria pinnatifida, showing the anti-P. falciparum activity of this compound (IC 50 = 2 μg mL −1 ). The in vivo analyses demonstrated that at a dose of 100 mg kg −1 day −1 , it was able to reduce the parasite burden by 37% in Plasmodium berghei-infected BALB/c mice, while the dose of 5 mg kg −1 day −1 of chloroquine was three times more effective, showing 94% of parasite burden reduction.
Other metabolites
A long chain aldehyde, (2E)-2-tridecylheptadec-2-enal (81), isolated from the dichloromethane extract of the red alga L. scoparia showed moderate in vitro anthelmintic activity (IC 50 < 100 μM) against the parasitant stage of N. brasiliensis; nevertheless, the compound was not as active as the reference drugs (e.g., albendazole, IC 50 = 0.34 μM) (Davyt et al. 2001) .
Patents
Over 2000 patents were searched considering the use of macroalgae as raw material for production of bioactive compound but none publication was found regarding NTDs. Furthermore, when being less restrictive, just eight patents were found when considering macroalgae as the resource of bioactive compound for medicinal preparations against viruses, parasites, and bacteria (Table 3) . Despite the aforementioned data regarding the seaweeds, bioactive compounds, and the very low number of registered and published patents, it is evident that this research field is being underexplored.
Discussion
Macroalgae are very important for the marine environment and are responsible for nitrate assimilation and O 2 production, while simultaneously removing CO 2 from the atmosphere. The compounds isolated from algae have sophisticated chemical structures and present great potential, considering the several published studies and patents regarding chemicals extracted from this marine source and registered for human health and nutrition (Cardozo et al. 2007; Torres et al. 2014) . It is a fact that the world population is increasing rapidly and, therefore, the demands for agricultural and food, new drugs for pharmaceutical purposes, metabolites for cosmetic, subproducts for the bioenergy industry, and many others are increasing and algae products and their metabolites can fulfill the gap of such demands. The bioactive compounds from marine algae herein described are very interesting for the pharmaceutical and medical areas, including drugs for NDs.
This review highlights the efforts of many research groups in finding bioactive compounds from marine algae to control NDs and circumvent the huge medical problem associated to the appearance of resistant pathogens. Indeed, Li et al. (2006) showed the potential of triterpenes obtained from the green alga P. capitus in inhibiting efflux pumps, membrane proteins known to be involved in multidrug resistance. Nevertheless, none of the compounds herein reported have been further evaluated in any clinical tests. A part of the problem is the reliance on the relative potency of the compounds or toxicity in comparison to the reference drugs, which make them not attractive to pharmaceutical companies in order to consider them as potential drug leads. Moreover, at least for some promising compounds, the small amounts of purified compounds are not sufficient for further evaluation in in vivo studies (Reichelt and Borowitzka, 1984) . Thus, to circumvent this issue, many efforts have been made in the synthesis and structural modification of marine bioactive compounds such as trabectedin (Cuevas and Francesch, 2009 ) and discodermolide (Freemantle, 2004; Mickel et al. 2004) , two anticancer agents that proceed thorough clinical trials. Trabecterin (Yondelis®) was approved by FDA in 2015 for the treatment of sarcomas (Barone et al. 2017) , while discodermolide failed at phase II/III due to their presented low efficacy and high toxicity (Freemantle, 2004; Mickel et al. 2004) .
Considering the chemical diversity observed among algal metabolites that were active against the etiological agents of NDs as their model microorganisms and the fewer studies approaching their mechanisms of action, it is not possible to suggest features of structure-bioactivity. Ogungbe and Setzer (2016) reviewed molecular targets for Leishmania, Trypanosoma, and Plasmodium spp. parasites and showed that several classes of phytochemicals, including geranylgeraniol, steroids, and phenols, presented an antioxidant enzyme, trypanothione reductase, as their target. In silico studies of algal metabolites could afford interesting insights concerning potential molecular targets such as those conducted by Passalacqua et al. (2015) , who performed docking analyses followed by dynamic simulation to investigate the molecular interactions and structural patterns that are crucial for the semisynthetic antileishmanial 2',4'-dihydroxychalcone targets the parasite glycolytic enzyme glycerol-3-phosphate dehydrogenase.
In response to this growing application, with a very high economic impact, it is imperative to take actions for the sustainable utilization and preservation of the natural resources. For this, farming cultivation of algae in open ponds, photobioreactors, or in tanks using IMTA has been stimulated by different governmental policies, and allied, modern, and environmentally green extraction methods are definitely changing the concept from wild harvesting to the sustainable production of algae in large scale (Laurens et al. 2017) . Moreover, the advancement of genetic techniques will allow isolation and expression of biosynthetic gene clusters important for production of therapeutically relevant secondary metabolites and the heterologous cloning of these genes in yeast or microalgae will represent a new frontier for natural products' drug discovery.
Despite the London Declaration of 2012 (Molyneux, 2016 ) and all the efforts of WHO, Research and Development commitments of pharmaceutical companies, and the huge diversity of NPs, this review revealed that we are far from the ideal scenario considering the search for new alternatives for treatment of NDs, especially those caused by helminthes. Part of the problem relies on the early stage drug discovery, which is a challenging step for most of the helminthes that, unlike protozoa or bacteria, present complex life cycles and do not have simple assays for drug screening. Indeed, drug discovery and development programs do not yet exist for any of the major helminth diseases, and only few works regarding bioactive NPs were found to be mildly effective against the nematode N. brasiliensis, known to infect only rodents. Although the use of N. brasiliensis as platform for drug discovery might be justified by its simple life cycle, similarity to other nematodes, and its use in animal models (Dominguez et al. 2000) , the drug discovery process for helminthes has been very slow. Therefore, more investment in the development of new and easy screening assays to find new therapeutic options to control these diseases is mandatory.
A low-cost and simple visual imaging system to automate and quantify screening of filariasis based on their movement has been proposed to search for new antifilarials (Marcellino et al. 2012) . For trematodes, the use of larval stages has been an alternative that allows the assessment of large numbers of worms (Abdulla et al. 2009 ). Nevertheless, although these achievements represent an important progress to the field of anti-helminthic discovery, these new assays are not comparable to the high throughput levels already established for the assays developed for the protozoa parasites Plasmodium spp., Trypanosoma sp., and Leishmania spp. (Hudson and Nwaka, 2007) . However, this scenario might be circumvented with the development of new approaches such as High Content Screening (HCS), recently developed for Schistosoma parasites and other helminths (Marcelino et al. 2012; Abdulla et al. 2009; Paveley, 2012) . Although HCS is slower when compared to HTS, it allows a more detailed phenotypic screening and better understanding of drug effects. Recently, a label-free HCS using automatic bright field image analysis was proposed for the assessment of anti-S. mansoni compounds. This system can be adapted to several other species of helminthes, which turns this assay into a promising alternative for drug discovery (Paveley et al. 2012) .
Even though phenotypic visual analysis is still the method of choice in many bioactive compound screening programs, target-based approaches must urgently be considered to be explored for scientists working on marine NPs. Simeonov et al. (2008) screened more than 71,000 synthetic compounds for thioredoxin/glutathione reductase and peroxiredoxin activity, principal components of the defense system of Schistosoma, and showed interesting hits presenting IC 50 values in the nanomolar range. This change of paradigm from phenotypic cell to target-based approach will definitely contribute to the discovery of more suitable bioactive NPs to combat these parasites. For this, other molecular targets are still necessary and the use of the technology of RNA interference (RNAi) has been very helpful for target identification and validation (Grant 2007; Geldhof et al. 2007; Grant e Behm, 2007; Yoshino et al. 2010; Maule et al. 2011; Dalzell et al. 2012; Crowther et al. 2014; Gosbert et al. 2014; He et al. 2018) . Besides, the search for new potential targets must consider not only their importance in pathogen survival and/or virulence but also their Bdruggability^, which might impair their use in HTS (Crowther et al. 2014 ).
Conclusion and perspectives
This review has highlighted the progress of early phase drug discovery for infectious diseases using as starting point the inexhaustible source of secondary metabolites, the marine macroalgae, and their potential for pharmaceutical application as well as some aspects of sustainable practices of cultivation and green extraction methods. From the 81 bioactive compounds highlighted in this review, 54 are terpenes and 14 are phenols, quinones, or related compounds, while macrolides, alkaloids, lipids, and polysaccharides were less reported. Among terpenes, the halogenated sesquiterpenes from Laurencia species (Rhodophyta) were the compounds that showed broad activity profile (antibacterial and antiparasitary) while non-halogenated diterpenes from the brown alga D. spiralis and bromoditerpenes from the red alga S. coronopifolius presented only reports for antibacterial activity against MRSA strains. The genus Sargassum presented the highest number of compounds in the class of phenolic compounds, where the prenylated toluquinones/quinols should be highlighted for the antibacterial and antiplasmodial activities. Among the reports from Laurencia species, it was possible to observe that some of the scientific names do not correspond to the currently accepted taxa. For example, Laurencia scoparia J. Agardh. as well as L. majuscula (Harvey) A.H.S. Lucas and L. obtusa var. majuscula Harvey have as accepted name Laurencia dendroidea J. Agardh. The high phenotypical variation of the genus Laurencia leads to common misidentification of the algal material, but the correct identification of other algal species may also be a considerable challenge. Furthermore, this review has also revealed the plethora of different screening protocols, strains, and data presentation, which turn difficult literature comparison. Thus, the development of specific guidelines for screening protocols for each bioactivity is mandatory and urgent.
